Goldman Sachs
NDRM

Goldman Sachs’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Goldman Sachs’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-369,029
Closed -$14.4M – 6988
2017
Q3 		$14.4M Buy
+369,029
New +$13.6M ﹤0.01% 2265
2017
Q2 		– Sell
-13,236
Closed -$351K – 7217
2017
Q1 		$351K Sell
13,236
-7,493
-36% -$186K ﹤0.01% 5325
2016
Q4 		$460K Buy
20,729
+8,342
+67% +$156K ﹤0.01% 5122
2016
Q3 		$229K Buy
+12,387
New +$215K ﹤0.01% 5714
2016
Q2 		– Sell
-104,334
Closed -$1.47M – 7571
2016
Q1 		$1.47M Buy
104,334
+16,995
+19% +$230K ﹤0.01% 3751
2015
Q4 		$1.49M Buy
+87,339
New +$1.7M ﹤0.01% 3906
2015
Q3 		– Sell
-18,051
Closed -$277K – 7807
2015
Q2 		$277K Buy
18,051
+7,144
+65% +$100K ﹤0.01% 5822
2015
Q1 		$146K Sell
10,907
-1,847
-14% -$22.7K ﹤0.01% 6231
2014
Q4 		$179K Buy
+12,754
New +$101K ﹤0.01% 6247

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Goldman Sachs's NDRM Position: Q4 2017 in Review

Goldman Sachs sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 369,029 shares — an estimated $14.4M sold.

Goldman Sachs first reported a position in NDRM in Q4 2014 and held it in 9 quarters. The position peaked at $14.4M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Goldman Sachs reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Goldman Sachs sold 369,029 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $14.4M.
  • Goldman Sachs first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 9 quarters.
  • Goldman Sachs's NeuroDerm Ltd. Ordinary Shares position peaked at $14.4M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.